Theriva Biologics Inc. (TOVX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
9605 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 23,177,000 | 41,786,000 | 67,325,000 | 6,227,000 | 15,045,000 | 28,918,000 | |||
| Cash and cash equivalents | 23,177,000 | 41,786,000 | 67,325,000 | 6,227,000 | 15,045,000 | 28,918,000 | |||
| Receivables | 1,940,000 | 87,000 | 469,000 | 3,000 | |||||
| Prepaid expense | 496,000 | 637,000 | 803,000 | 639,000 | 25,000 | 42,000 | |||
| Other undisclosed current assets | 1,790,000 | 3,010,000 | 730,000 | 599,000 | 1,353,000 | 551,000 | |||
| Total current assets: | 27,403,000 | 45,520,000 | 68,858,000 | 7,934,000 | 16,426,000 | 29,511,000 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,759,000 | 1,199,000 | 1,383,000 | 279,000 | 419,000 | ✕ | |||
| Property, plant and equipment | 422,000 | 345,000 | 101,000 | 174,000 | 367,000 | 607,000 | |||
| Intangible assets, net (including goodwill) | 25,455,000 | 24,675,000 | |||||||
| Goodwill | 5,700,000 | 5,525,000 | |||||||
| Intangible assets, net (excluding goodwill) | 19,755,000 | 19,150,000 | |||||||
| Restricted cash and investments | 102,000 | 99,000 | |||||||
| Other undisclosed noncurrent assets | 78,000 | 23,000 | 23,000 | 23,000 | 23,000 | 23,000 | |||
| Total noncurrent assets: | 27,816,000 | 26,341,000 | 1,507,000 | 476,000 | 809,000 | 630,000 | |||
| TOTAL ASSETS: | 55,219,000 | 71,861,000 | 70,365,000 | 8,410,000 | 17,235,000 | 30,141,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 3,765,000 | 2,411,000 | 3,430,000 | 2,679,000 | 5,026,000 | 3,285,000 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 978,000 | 868,000 | 935,000 | 1,332,000 | ||
| Accounts payable | 770,000 | 915,000 | 524,000 | 886,000 | 2,315,000 | 1,034,000 | |||
| Accrued liabilities | 2,995,000 | 1,496,000 | 1,928,000 | 925,000 | 1,776,000 | 919,000 | |||
| Deferred revenue | 906,000 | ✕ | |||||||
| Debt | 126,000 | 114,000 | 249,000 | ||||||
| Deferred rent credit | 99,000 | ||||||||
| Business combination, contingent consideration, liability | 2,973,000 | ||||||||
| Other undisclosed current liabilities | 1,941,000 | 1,562,000 | 124,000 | 287,000 | |||||
| Total current liabilities: | 6,738,000 | 7,060,000 | 3,554,000 | 2,966,000 | 5,275,000 | 3,384,000 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 162,000 | 221,000 | 1,403,000 | 186,000 | 473,000 | ||||
| Long-term debt, excluding current maturities | 162,000 | 221,000 | |||||||
| Liabilities, other than long-term debt | 8,622,000 | 10,016,000 | 302,000 | ||||||
| Deferred revenue | 906,000 | ✕ | |||||||
| Deferred rent credit | 302,000 | ||||||||
| Deferred income tax liabilities | 1,618,000 | ✕ | |||||||
| Operating lease, liability | 1,442,000 | 1,187,000 | 1,403,000 | 186,000 | 473,000 | ✕ | |||
| Business combination, contingent consideration, liability | 6,274,000 | 7,211,000 | |||||||
| Other undisclosed noncurrent liabilities | (1,403,000) | (186,000) | |||||||
| Total noncurrent liabilities: | 8,784,000 | 10,237,000 | 1,403,000 | 186,000 | 473,000 | 302,000 | |||
| Total liabilities: | 15,522,000 | 17,297,000 | 4,957,000 | 3,152,000 | 5,748,000 | 3,686,000 | |||
| Temporary equity, carrying amount | 12,798,000 | 12,544,000 | 12,296,000 | ||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | 36,963,000 | 51,830,000 | 65,408,000 | (4,767,000) | 1,821,000 | 17,068,000 | |||
| Preferred stock | 2,477,000 | ||||||||
| Common stock | 18,000 | 16,000 | 132,000 | 29,000 | 17,000 | 15,000 | |||
| Treasury stock, value | (288,000) | (288,000) | |||||||
| Additional paid in capital | 346,519,000 | 343,750,000 | 336,560,000 | 240,821,000 | 232,580,000 | 230,754,000 | |||
| Accumulated other comprehensive income (loss) | 32,000 | (679,000) | |||||||
| Accumulated deficit | (309,318,000) | (290,969,000) | (271,284,000) | (248,094,000) | (235,537,000) | (219,461,000) | |||
| Other undisclosed equity, attributable to parent | 4,761,000 | 5,760,000 | |||||||
| Equity, attributable to noncontrolling interest | (2,773,000) | (2,878,000) | (2,909,000) | ||||||
| Total equity: | 36,963,000 | 51,830,000 | 65,408,000 | (7,540,000) | (1,057,000) | 14,159,000 | |||
| Other undisclosed liabilities and equity | 2,734,000 | 2,734,000 | |||||||
| TOTAL LIABILITIES AND EQUITY: | 55,219,000 | 71,861,000 | 70,365,000 | 8,410,000 | 17,235,000 | 30,141,000 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (21,431,000) | (21,581,000) | (14,274,000) | (10,160,000) | (15,663,000) | (17,571,000) | ||
| Operating loss: | (21,431,000) | (21,581,000) | (14,274,000) | (10,160,000) | (15,663,000) | (17,571,000) | ||
| Nonoperating income | 1,442,000 | 471,000 | 6,000 | 44,000 | 283,000 | 4,150,000 | ||
| Investment income, nonoperating | 1,439,000 | 512,000 | 6,000 | 44,000 | 283,000 | 67,000 | ||
| Loss from continuing operations before income taxes: | (19,989,000) | (21,110,000) | (14,268,000) | (10,116,000) | (15,380,000) | (13,421,000) | ||
| Income tax benefit | 1,640,000 | 1,425,000 | 3,976,000 | 2,740,000 | ||||
| Loss from continuing operations: | (18,349,000) | (19,685,000) | (10,292,000) | (7,376,000) | (15,380,000) | (13,421,000) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (10,292,000) | (7,376,000) | (15,380,000) | (13,421,000) | |
| Other undisclosed net loss | (3,976,000) | (2,740,000) | ||||||
| Net loss: | (18,349,000) | (19,685,000) | (14,268,000) | (10,116,000) | (15,380,000) | (13,421,000) | ||
| Net income attributable to noncontrolling interest | 1,000 | 73,000 | 77,000 | 54,000 | ||||
| Net loss attributable to parent: | (18,349,000) | (19,685,000) | (14,267,000) | (10,043,000) | (15,303,000) | (13,367,000) | ||
| Preferred stock dividends and other adjustments | (254,000) | (248,000) | (243,000) | |||||
| Other undisclosed net loss available to common stockholders, basic | (340,000) | (8,922,000) | (2,260,000) | (525,000) | (11,681,000) | |||
| Net loss available to common stockholders, diluted: | (18,349,000) | (20,025,000) | (23,189,000) | (12,557,000) | (16,076,000) | (25,291,000) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (18,349,000) | (19,685,000) | (14,268,000) | (10,116,000) | (15,380,000) | (13,421,000) | ||
| Other undisclosed comprehensive income (loss) | 711,000 | (679,000) | ||||||
| Comprehensive loss: | (17,638,000) | (20,364,000) | (14,268,000) | (10,116,000) | (15,380,000) | (13,421,000) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 1,000 | 73,000 | 77,000 | 54,000 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (17,638,000) | (20,364,000) | (14,267,000) | (10,043,000) | (15,303,000) | (13,367,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.